Based on technology developed within the neuroscience laboratories of Washington University School of Medicine, Saint Louis, MO, LifeTech Research, Inc. of Baltimore MD co-founded C2N Diagnostics. The firm is usefully understood as a specialty diagnostics company structured around accelerating novel diagnostics and therapies for Alzheimer's disease. The company offers precise, accurate, and sensitive mass spectrometry-based identification, quantification, and monitoring of proteins, protein fragments, and other biomolecules implicated in human neurological diseases, enabling doctors to detect and characterize neurocognitive disorders. The vision of C?N Diagnostics personnel is to bring Clarity Through Innovation. The firm focuses its therapeutic discovery efforts around mechanism-based approaches to prevent or stop the progression of human neurological disorders. Diagnostic efforts revolve around bringing accurate, widely accessible, and cost-effective blood tests to the clinic for the betterment of patient care and brain health monitoring. Its lead commercial product -- the PrecivityAD blood test -- is a mass spectrometry-based test performed in C?Ns CLIA-certified lab that measures in blood multiple analytes including A?42, A?40, and apolipoprotein E isoforms. While the test by itself cannot diagnose Alzheimers disease which is a clinical diagnosis made by a health care provider the test is an important new tool for physicians to aid in the ev
